MYD88 and B-cell non-Hodgkin lymphoma: Conversely, MyD88-IRAK-4 signaling plays a critical role in B cell lymphomas when constitutively induced by MyD88 gain-of-function mutations which lead to constitutive Myddosome assembly12, 13.